Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

61. Cholesterol: slightly higher risk of type 2 diabetes with all statins

Cholesterol: slightly higher risk of type 2 diabetes with all statins Prescrire IN ENGLISH - Spotlight ''Cholesterol: slightly higher risk of type 2 diabetes with all statins'', 1 January 2017 {1} {1} {1} | | > > > Cholesterol: slightly higher risk of type 2 diabetes with all statins Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Cholesterol (...) : slightly higher risk of type 2 diabetes with all statins Several large-scale studies have revealed an increased risk of type 2 diabetes in patients taking a statin. Statins are widely used to lower cholesterol, in the hope of reducing the risk of premature death and major cardiovascular events (myocardial infarction, ischaemic stroke). A review has been carried out of 13 studies which included patient follow-up for at least one year. Some 91,000 non-diabetic participants were monitored for 4 years

2017 Prescrire

62. Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study Full Text available with Trip Pro

Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study Disease-modifying drugs are not yet available for the management of chronic obstructive pulmonary disease (COPD). HMG-CoA reductase inhibitors (statins) have anti-inflammatory properties and are therefore being considered for use in the management of COPD.Our objective was to examine the association between statin use and COPD-specific outcomes in a real-world setting.This was a retrospective (...) longitudinal dynamic cohort study that used Medicaid claims data from multiple years (2005-2008) to identify patients with newly diagnosed COPD. Statin therapy was determined from the prescription drug file using National Drug Codes (NDCs). COPD-specific outcomes such as hospitalizations and emergency room and outpatient visits were identified based on a primary diagnosis of COPD. Multivariable logistic regressions with inverse probability treatment weights (IPTWs) were used to examine the relationship

2016 Drugs - real world outcomes

63. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis Full Text available with Trip Pro

Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis Patients with rheumatoid arthritis (RA) have decreased survival because of increased cardiovascular risk compared with the general population, and treatment with tocilizumab (TCZ) has been shown to increase lipid levels; however, the relationship between lipids and cardiovascular risk is unknown. This post hoc analysis expanded on previously reported 24-week results by characterizing statin (...) of the intention-to-treat populations in the TCZ-IV and TCZ-SC studies, and results were stratified by concomitant statin use.Data from this descriptive, retrospective, pooled analysis indicated that statins can stabilize lipid levels without a clinically significant increase in adverse events. Approximately 30% of patients in the TCZ treatment arms who never received a statin demonstrated a shift in low-density-lipoprotein cholesterol (LDL-C) from <130 mg/dl at baseline to ≥130 mg/dl at 2 years. However

2016 Rheumatology and therapy Controlled trial quality: uncertain

64. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults.To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults.The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment (...) of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events.The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD

2016 JAMA

65. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental LDL-C lowering in statin-treated patients; however, the effects of these drugs on coronary atherosclerosis have (...) not been evaluated.To determine the effects of PCSK9 inhibition with evolocumab on progression of coronary atherosclerosis in statin-treated patients.The GLAGOV multicenter, double-blind, placebo-controlled, randomized clinical trial (enrollment May 3, 2013, to January 12, 2015) conducted at 197 academic and community hospitals in North America, Europe, South America, Asia, Australia, and South Africa and enrolling 968 patients presenting for coronary angiography.Participants with angiographic coronary

2016 JAMA Controlled trial quality: predicted high

66. Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence Full Text available with Trip Pro

., Extramural Research Support, Non-U.S. Gov't United States JAMA 7501160 0098-7484 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AIM IM JAMA. 2017 Mar 14;317(10 ):1081 28291887 Aged Aged, 80 and over Atherosclerosis prevention & control Cardiovascular Diseases prevention & control Evidence-Based Medicine Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects therapeutic use Practice Guidelines as Topic Primary Prevention Randomized Controlled Trials as Topic Risk 2016 11 14 6 0 2016 11 14 (...) Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence 27838724 2016 12 13 2018 11 13 1538-3598 316 19 2016 Nov 15 JAMA JAMA Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence. 1971-1972 10.1001/jama.2016.15212 Gurwitz Jerry H JH Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Fallon Health, and Reliant Medical Group, Worcester, Massachusetts2Division of Geriatric Medicine

2016 JAMA

67. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia Full Text available with Trip Pro

Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia Statin therapy is associated with a slightly increased risk of developing diabetes mellitus and insulin resistance in patients without diabetes. Ezetimibe combined with statins may be considered for high-risk patients who do not achieve optimal low-density lipoprotein cholesterol lowering on statin monotherapy or who are statin intolerant. Changes in fasting serum glucose (FSG (...) ) levels during ezetimibe, ezetimibe/statin, and statin treatments were assessed using data pooled from clinical trials in hypercholesterolemic and heterozygous familial hypercholesterolemic patients, who were or were not receiving statin therapy. Study types included first-line trials in statin-naive/wash-out patients and second-line add-on and uptitration studies in patients on stable statin therapy. Similar analyses of FSG changes were performed separately for each study type in patients who were

2016 EvidenceUpdates

68. Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study (Abstract)

1000 person-years versus 14.9, 4.6, 6.2, and 2.5 events per 1000 person-years among controls, respectively. In patients with GCA, cardiovascular comorbidities at diagnosis (HR 6.2, 2.0-19.2), age over 77 years (HR 5.0, 1.40-17.54), as well as the cumulative defined daily dose of statins (HR 0.993, 0.986-0.999) were independent predictors for subsequent cardiovascular hospitalization. None of the 25 patients with GCA who were taking platelet aggregation inhibitors experienced a cardiovascular (...) Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study To identify predictors and protectors for cardiovascular hospitalization in a giant cell arteritis (GCA) population-based cohort.Using the French National Health Insurance system, we included patients with incident GCA from the Midi-Pyrenees region, southern France, from January 2005 to December 2008 and randomly selected 6 controls matched by sex and age at calendar

2016 EvidenceUpdates

69. PCSK9 Inhibitors: Who Could Need More than a Statin?

PCSK9 Inhibitors: Who Could Need More than a Statin? PCSK9 Inhibitors: Who Could Need More than a Statin? – Clinical Correlations Search PCSK9 Inhibitors: Who Could Need More than a Statin? October 5, 2016 5 min read By Rhodes Hambrick Peer Reviewed The atherosclerotic cardiovascular disease (ASCVD) risk associated with hyperlipidemia (HLD), readily of the mid-20 th century, has been the target of innumerable attempted pharmacologic interventions ever since. One class of agents, the HMG-CoA (...) reductase inhibitors, or statins, became – and have remained 2 – the gold standard for managing HLD-associated ASCVD risk in the setting of the remarkably favorable findings of multiple studies in the 1990s. 3-5 While other agents, including niacin, fish oil, and fibrates, have been demonstrated to have favorable effects on some combination of LDL, HDL, and triglycerides, only statins have been conclusively proven to be of consistent, predictable benefit in reducing ASCVD-related morbidity and mortality

2016 Clinical Correlations

70. Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial Full Text available with Trip Pro

Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial Simple nudges such as reminders and feedback reports to either a patient or a partner may facilitate improved medication adherence.To test the impact of a pill bottle used to monitor adherence, deliver a daily alarm, and generate weekly medication adherence feedback reports on statin adherence.Three-month, three-arm randomized clinical trial (ClinicalTrials.gov identifier: NCT02480530).One (...) and = 0.001). At 6 months, there was no difference in medication adherence between either of the feedback groups and the control (individual feedback 60 %, partner feedback 52 %, control group 54 %; p = 0.75 and 0.97).Daily alarms combined with individual or partner feedback reports improved statin medication adherence. While neither an individual feedback nor partner feedback strategy created a sustainable medication adherence habit, the intervention itself is relatively easy to implement and low cost.

2016 EvidenceUpdates Controlled trial quality: uncertain

71. Statin withdrawal in people with dementia. Full Text available with Trip Pro

Statin withdrawal in people with dementia. There are approximately 24 million people worldwide with dementia; this is likely to increase to 81 million by 2040. Dementia is a progressive condition, and usually leads to death eight to ten years after first symptoms. End-of-life care should emphasise treatments that optimise quality of life and physicians should minimise unnecessary or non-beneficial interventions. Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (...) ; they have become the cornerstone of pharmacotherapy for the management of hypercholesterolaemia but their ability to provide benefit is unclear in the last weeks or months of life. Withdrawal of statins may improve quality of life in people with advanced dementia, as they will not be subjected to unnecessary polypharmacy or side effects. However, they may help to prevent further vascular events in people of advanced age who are at high risk of such events.To evaluate the effects of withdrawal

2016 Cochrane

72. Interpretation of the evidence for the efficacy and safety of statin therapy. Full Text available with Trip Pro

Interpretation of the evidence for the efficacy and safety of statin therapy. This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect (...) a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend

2016 Lancet

73. Statins for aortic valve stenosis. Full Text available with Trip Pro

Statins for aortic valve stenosis. Aortic valve stenosis is the most common type of valvular heart disease in the USA and Europe. Aortic valve stenosis is considered similar to atherosclerotic disease. Some studies have evaluated statins for aortic valve stenosis.To evaluate the effectiveness and safety of statins in aortic valve stenosis.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS - IBECS, Web of Science and CINAHL Plus. These databases (...) were searched from their inception to 24 November 2015. We also searched trials in registers for ongoing trials. We used no language restrictions.Randomised controlled clinical trials (RCTs) comparing statins alone or in association with other systemic drugs to reduce cholesterol levels versus placebo or usual care.Primary outcomes were severity of aortic valve stenosis (evaluated by echocardiographic criteria: mean pressure gradient, valve area and aortic jet velocity), freedom from valve

2016 Cochrane

74. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study Full Text available with Trip Pro

A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend primary prevention with statins for individuals with ≥7.5% 10-year risk for atherosclerotic cardiovascular disease (ASCVD). Everyone living long enough will become eligible for risk-based statin therapy due to age alone.This study sought to personalize ACC/AHA risk-based (...) statin eligibility using noninvasive assessment of subclinical atherosclerosis.In 5,805 BioImage participants without known ASCVD at baseline, those with ≥7.5% 10-year ASCVD risk were down-classified from statin eligible to ineligible if imaging revealed no coronary artery calcium (CAC) or carotid plaque burden (cPB). Intermediate-risk individuals were up-classified from optional to clear statin eligibility if CAC was ≥100 (or equivalent cPB).At a median follow-up of 2.7 years, 91 patients had

2016 EvidenceUpdates

75. Statin Use and Survival After Acute Kidney Injury Full Text available with Trip Pro

Statin Use and Survival After Acute Kidney Injury The incidence of acute kidney injury (AKI) in hospitalized patients is rising, and survivors are at high risk for cardiovascular events and mortality. Effective strategies that improve long-term outcomes of AKI are unknown.A retrospective cohort study was performed between 2008 and 2011. All subjects were followed until 31 March 2013, with a minimum follow-up of 2 years. Participants were adults 18 years of age or older, who developed AKI (...) during a hospitalization and had chronic kidney disease (CKD) following discharge (n = 19,707 mean age 69.9 years, mean postdischarge estimated glomerular filtration rate (eGFR) 43.0 ml/min/1.73 m2). Exposure to statins was examined prior to the index hospitalization as well as within 2 years following hospital discharge. The primary outcome was mortality; secondary outcomes included all-cause re-hospitalization and cardiovascular events.Within 2 years of discharge, only 38.3% of the participants

2016 Kidney international reports

76. Statins for age-related macular degeneration. Full Text available with Trip Pro

Statins for age-related macular degeneration. Age-related macular degeneration (AMD) is a progressive, late-onset disorder of the macula affecting central vision. It is the leading cause of blindness in people over 65 years in industrialized countries. Recent epidemiologic, genetic, and pathological evidence has shown that AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD.The objective of this review (...) was to examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and progression of AMD.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 3), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to March 2016), EMBASE (January 1980 to March 2016), Latin American and Caribbean Health

2016 Cochrane

77. Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. Full Text available with Trip Pro

Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. Inflammation may contribute to pathological associations among obesity, diabetes mellitus, and cardiovascular disease.To determine whether targeting inflammation using salsalate compared with placebo reduces progression of noncalcified coronary artery plaque.In the Targeting Inflammation Using Salsalate in Cardiovascular (...) Disease (TINSAL-CVD) trial participants were randomly assigned between September 23, 2008, and July 5, 2012, to 30 months of salsalate or placebo in addition to standard, guideline-based therapies. Randomization was computerized and centrally allocated, with patients, health care professionals, and researchers masked to treatment assignment. Participants were overweight and obese statin-using patients with established, stable coronary heart disease.Salsalate (3.5 g/d) or placebo orally over 30

2016 JAMA cardiology Controlled trial quality: predicted high

78. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. Full Text available with Trip Pro

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database.  To estimate rates of discontinuation and restarting of statins, and to identify patient characteristics associated with either discontinuation or restarting. Prospective open cohort study. 664 general practices contributing to the Clinical Practice Research Datalink in the United Kingdom. Data extracted in October 2014. Incident statin users aged 25-84 years identified (...) between January 2002 and September 2013. Patients with statin prescriptions divided into two groups: primary prevention and secondary prevention (those already diagnosed with cardiovascular disease). Patients with statin prescriptions in the 12 months before study entry were excluded. Discontinuation of statin treatment (first 90 day gap after the estimated end date of a statin prescription), and restarting statin treatment for those who discontinued (defined as any subsequent prescription between

2016 BMJ

79. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. Full Text available with Trip Pro

Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data.  To quantify how a period of intense media coverage of controversy over the risk:benefit balance of statins affected their use. Interrupted time series analysis of prospectively collected electronic data from primary care. Clinical Practice Research Datalink (CPRD) in the United Kingdom. Patients newly eligible for or currently taking statins for primary and secondary (...) cardiovascular disease prevention in each month in January 2011-March 2015. Adjusted odds ratios for starting/stopping taking statins after the media coverage (October 2013-March 2014). There was no evidence that the period of high media coverage was associated with changes in statin initiation among patients with a high recorded risk score for cardiovascular disease (primary prevention) or a recent cardiovascular event (secondary prevention) (odds ratio 0.99 (95% confidence interval 0.87 to 1.13; P=0.92

2016 BMJ

80. PCSK9 Inhibitors for Statin Intolerance? Full Text available with Trip Pro

PCSK9 Inhibitors for Statin Intolerance? 27039138 2016 05 02 2018 12 02 1538-3598 315 15 2016 Apr 19 JAMA JAMA PCSK9 Inhibitors for Statin Intolerance? 1571-2 10.1001/jama.2016.3670 Waters David D DD Division of Cardiology, San Francisco General Hospital, San Francisco, California2Department of Medicine, University of California-San Francisco. Hsue Priscilla Y PY Division of Cardiology, San Francisco General Hospital, San Francisco, California2Department of Medicine, University of California

2016 JAMA